The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 09, 2026

Filed:

Jan. 26, 2021
Applicant:

Corcept Therapeutics Incorporated, Menlo Park, CA (US);

Inventors:

Andrew Greenstein, Menlo Park, CA (US);

Andreas Grauer, Menlo Park, CA (US);

Stacie Shepherd, Menlo Park, CA (US);

Assignee:

Corcept Therapeutics Incorporated, Redwood City, CA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61P 5/38 (2006.01); A61K 31/337 (2006.01); A61K 31/4745 (2006.01); A61K 31/513 (2006.01); A61K 31/7068 (2006.01); A61K 33/243 (2019.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 31/4745 (2013.01); A61K 31/337 (2013.01); A61K 31/513 (2013.01); A61K 31/7068 (2013.01); A61K 33/243 (2019.01); A61K 39/3955 (2013.01); A61P 5/38 (2018.01); A61P 35/00 (2018.01); A61K 2039/505 (2013.01);
Abstract

Methods and compositions for treating a subject suffering from adrenocortical carcinoma and having excess cortisol are disclosed. The methods provide therapeutic benefits including reduction of ACC tumor load, restoration of T-cell and natural killer (NK) cell signaling pathways, increase in T-cell and NK cell infiltration into the ACC tumor, reduction of neutrophil infiltration into the ACC tumor in the patient, and other therapeutic benefits. The methods include administration of a glucocorticoid receptor modulator (GRM) (which may be a selective glucocorticoid receptor modulator (SGRM)) and an antibody checkpoint inhibitor. In embodiments, the GRM (e.g., a SGRM) is orally administered. The GRM may be a nonsteroidal compound comprising: a fused azadecalin structure; a heteroaryl ketone fused azadecalin structure; or an octahydro fused azadecalin structure.


Find Patent Forward Citations

Loading…